| Year |
Citation |
Score |
| 2022 |
Galloway DR, Nguyen NX, Li J, Houston N, Gregersen G, Williamson ED, Falkenberg FW, Herron JN, Hale JS. The magnitude of the germinal center B cell and T follicular helper cell response predicts long-lasting antibody titers to plague vaccination. Frontiers in Immunology. 13: 1017385. PMID 36389793 DOI: 10.3389/fimmu.2022.1017385 |
0.33 |
|
| 2022 |
Moore BD, Macleod C, Henning L, Krile R, Chou YL, Laws TR, Butcher WA, Moore KM, Walker NJ, Williamson ED, Galloway DR. Predictors of Survival after Vaccination in a Pneumonic Plague Model. Vaccines. 10. PMID 35214604 DOI: 10.3390/vaccines10020145 |
0.328 |
|
| 2011 |
Brenneman KE, Doganay M, Akmal A, Goldman S, Galloway DR, Mateczun AJ, Cross AS, Baillie LW. The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax. Fems Immunology and Medical Microbiology. 62: 164-72. PMID 21401726 DOI: 10.1111/J.1574-695X.2011.00800.X |
0.43 |
|
| 2007 |
Legutki JB, Nelson M, Titball R, Galloway DR, Mateczun A, Baillie LW. Analysis of peptide mimotopes of Burkholderia pseudomallei exopolysaccharide. Vaccine. 25: 7796-805. PMID 17935838 DOI: 10.1016/J.Vaccine.2007.08.045 |
0.351 |
|
| 2007 |
Albrecht MT, Li H, Williamson ED, LeButt CS, Flick-Smith HC, Quinn CP, Westra H, Galloway D, Mateczun A, Goldman S, Groen H, Baillie LW. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infection and Immunity. 75: 5425-33. PMID 17646360 DOI: 10.1128/Iai.00261-07 |
0.404 |
|
| 2004 |
Kim TG, Galloway DR, Langridge WH. Synthesis and assembly of anthrax lethal factor-cholera toxin B-subunit fusion protein in transgenic potato. Molecular Biotechnology. 28: 175-83. PMID 15542917 DOI: 10.1385/Mb:28:3:175 |
0.365 |
|
| 2004 |
Galloway DR, Baillie L. DNA vaccines against anthrax. Expert Opinion On Biological Therapy. 4: 1661-7. PMID 15461577 DOI: 10.1517/14712598.4.10.1661 |
0.343 |
|
| 2004 |
Hermanson G, Whitlow V, Parker S, Tonsky K, Rusalov D, Ferrari M, Lalor P, Komai M, Mere R, Bell M, Brenneman K, Mateczun A, Evans T, Kaslow D, Galloway D, et al. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proceedings of the National Academy of Sciences of the United States of America. 101: 13601-6. PMID 15342913 DOI: 10.1073/Pnas.0405557101 |
0.408 |
|
| 2004 |
Hoffmaster AR, Ravel J, Rasko DA, Chapman GD, Chute MD, Marston CK, De BK, Sacchi CT, Fitzgerald C, Mayer LW, Maiden MCJ, Priest FG, Barker M, Jiang L, Cer RZ, ... ... Galloway DR, et al. Identification of anthrax toxin genes in a bacillus cereus associated with an illness resembling inhalation anthrax Proceedings of the National Academy of Sciences of the United States of America. 101: 8449-8454. PMID 15155910 DOI: 10.1073/Pnas.0402414101 |
0.35 |
|
| 2004 |
Galloway D, Liner A, Legutki J, Mateczun A, Barnewall R, Estep J. Genetic immunization against anthrax. Vaccine. 22: 1604-1608. PMID 15068841 DOI: 10.1016/J.Vaccine.2003.09.043 |
0.439 |
|
| 2002 |
Price BM, Barten Legutki J, Galloway DR, von Specht BU, Gilleland LB, Gilleland HE, Staczek J. Enhancement of the protective efficacy of an oprF DNA vaccine against Pseudomonas aeruginosa. Fems Immunology and Medical Microbiology. 33: 89-99. PMID 12052563 DOI: 10.1111/J.1574-695X.2002.Tb00577.X |
0.408 |
|
| 2001 |
Price BM, Liner AL, Park S, Leppla SH, Mateczun A, Galloway DR. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein Infection and Immunity. 69: 4509-4515. PMID 11401993 DOI: 10.1128/Iai.69.7.4509-4515.2001 |
0.439 |
|
| 2001 |
Price BM, Galloway DR, Baker NR, Gilleland LB, Staczek J, Gilleland J. Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunization against outer membrane protein F (OprF) of P. aeruginosa Infection and Immunity. 69: 3510-3515. PMID 11292786 DOI: 10.1128/Iai.69.5.3510-3515.2001 |
0.444 |
|
| 2000 |
Denis-Mize KS, Price BM, Baker NR, Galloway DR. Analysis of immunization with DNA encoding Pseudomonas aeruginosa exotoxin A Fems Immunology and Medical Microbiology. 27: 147-154. PMID 10640610 DOI: 10.1111/J.1574-695X.2000.Tb01425.X |
0.438 |
|
| 1998 |
Park S, Galloway DR. Pseudomonas aeruginosa LasD processes the inactive LasA precursor to the active protease form Archives of Biochemistry and Biophysics. 357: 8-12. PMID 9721177 DOI: 10.1006/Abbi.1998.0787 |
0.346 |
|
| 1995 |
Han XY, Galloway DR. Active site mutations of Pseudomonas aeruginosa exotoxin A. Analysis of the His440 residue Journal of Biological Chemistry. 270: 679-684. PMID 7822295 DOI: 10.1074/Jbc.270.2.679 |
0.307 |
|
| 1995 |
Park S, Galloway DR. Purification and characterization of LasD: a second staphylolytic proteinase produced by Pseudomonas aeruginosa Molecular Microbiology. 16: 263-270. PMID 7565088 DOI: 10.1111/J.1365-2958.1995.Tb02298.X |
0.387 |
|
| 1992 |
Peters JE, Park SJ, Darzins A, Freck LC, Saulnier JM, Wallach JM, Galloway DR. Further studies on Pseudomonas aeruginosa LasA: analysis of specificity Molecular Microbiology. 6: 1155-1162. PMID 1588815 DOI: 10.1111/J.1365-2958.1992.Tb01554.X |
0.351 |
|
| 1988 |
Wozniak DJ, Hsu LY, Galloway DR. His-426 of the Pseudomonas aeruginosa exotoxin A is required for ADP-ribosylation of elongation factor II. Proceedings of the National Academy of Sciences of the United States of America. 85: 8880-4. PMID 3143111 DOI: 10.1073/Pnas.85.23.8880 |
0.42 |
|
| 1987 |
Wozniak DJ, Cram DC, Daniels CJ, Galloway DR. Nucleotide sequence and characterization of toxR: a gene involved in exotoxin A regulation in Pseudomonas aeruginosa. Nucleic Acids Research. 15: 2123-35. PMID 3031589 DOI: 10.1093/Nar/15.5.2123 |
0.322 |
|
| 1984 |
Galloway DR, Hedstrom RC, Pavlovskis OR. Production and characterization of monoclonal antibodies to exotoxin A from Pseudomonas aeruginosa Infection and Immunity. 44: 262-267. PMID 6425217 |
0.319 |
|
| Show low-probability matches. |